The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis

Gut

Volumn 56, Issue 4, 2007, Pages 565-574

  Yamazaki, Yuichi ^a   Kakizaki, Satoru ^a   Horiguchi, Norio ^a   Sohara, Naondo ^a   Sato, Ken ^a   Takagi, Hitoshi ^a   Mori, Masatomo ^a   Negishi, Masahiko ^b  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B; CYTOCHROME P450 2B10; CYTOCHROME P450 2C; CYTOCHROME P450 2C29; CYTOCHROME P450 3A11; METHIONINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; DATA ANALYSIS; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LIVER FIBROSIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; VITAMIN DEFICIENCY; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; BODY WEIGHT; CHOLINE DEFICIENCY; DIET; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION REGULATION; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; MALE; METHIONINE; MICE; MICE, KNOCKOUT; ORGAN SIZE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 34147212096     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.093260     Document Type: Article

References (27)

1. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
2. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-62.
3. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
4. Menta K, Van Thiel DH, Shah N, et al. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002;60:289-93.
5. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171-80.
6. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-75.
7. Honkakoski P, Moore R, Washburn K, et al. Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol Pharmacol 1998;53:597-601.
8. Honkakoski P, Zelko I, Sueyoshi T, et al. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 1998;18:5652-8.
9. Sueyoshi T, Kawamoto T, Zelko I, et al. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999;274:6043-6.
10. Sugatani J, Kojima H, Ueda A, et al. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 2001;33:1232-8.
11. Xie W, Yeuh MF, Radominska-Pandya A, et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 2003;100:4150-5.
12. Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002;277:2908-15.
13. Cherrington NJ, Hartley DP, Li N, et al. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 2002;300:97-104.
14. Cotrim HP, Andrade ZA, Parana R, et al. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999;19:299-304.
15. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
16. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
17. Yamamoto Y, Moore R, Goldsworthy TL, et al. The orphan nuclear receptor CAR is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 2004;64:7197-200.
18. Ueda A, Hamadeh HK, Webb HK, et al. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 2002;61:1-6.
19. Folch J, Less M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497-509.
20. Toell A, Kroncke KD, Kleinert H, et al. Orphan nuclear receptor binding site in the human inducible nitric oxide synthase promoter mediates responsiveness to steroid and xenobiotic ligands. J Cell Biochem 2002;85:72-82.
21. Lieber CS, Leo MA, Mak KM, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004;79:502-9.
22. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645-53.
23. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27:128-33.
24. Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003;37:544-50.
25. Kono H, Bradford BU, Yin M, et al. CYP2E1 is not involved in early alcohol-induced liver injury. Am J Physiol 1999;277: G1259-67.
26. Ip E, Farrell GC, Robertson G, et al. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003;38:123-32.
27. Ip E, Farrell G, Hall P, et al. Administration of the potent PPARalpha agonist, Wy14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004;39:1286-96.